Doctors test personalized cancer vaccine in small ovarian cancer study
NCT ID NCT02111941
Summary
This small, early-stage study tested a personalized vaccine for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The vaccine was made from a patient's own white blood cells, trained to target a protein found on cancer cells. The main goals were to check if the vaccine was safe and to see if it could trigger the patient's immune system to attack the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN SEROMUCINOUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.